Nifty
:
24211.00
Sensex
:
77616.40
4.10 (0.02%)
47.01 (0.06%)
Nifty
Sensex
:
:
24211.00
77616.40
4.10 (0.02%)
47.01 (0.06%)

Concord Biotech Ltd.

Pharmaceuticals & Drugs

Rating :
44/99

BSE: 543960 | NSE: CONCORDBIO

NSE BSE
1351.70
13-Jul-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1296.1
  •  1360
  •  1271
  •  1304.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  150971
  •  201222368.4
  •  1980
  •  987

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 14,148.30
  • 54.23
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 14,134.72
  • 0.56%
  • 7.01

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 44.08%
  • 2.03%
  • 8.09%
  • FII
  • DII
  • Others
  • 7.79%
  • 8.19%
  • 29.82%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.61
  • 8.15
  • 1.23

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.58
  • 6.08
  • -3.17

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.24
  • 8.32
  • -5.39

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 52.42

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 10.89

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 34.62

Earnings Forecasts:

(Updated: 11-07-2026)
Description
2026
2027
2028
2029
Adj EPS
31
-2
18.9
30.8
P/E Ratio
43.60
-675.85
71.52
43.89
Revenue
36.15
29.54
27.16
1164
EBITDA
1319.78
1567.22
1729.48
418.03
Net Income
488.8
604.52
673.87
298.25
ROA
352.62
441.9
495.25
13.84
P/B Ratio
-2.67
-2.05
-
7.11
ROE
5.97
5.24
4.66
15.54
FCFF
16.38
18.22
17.85
304.44
FCFF Yield
246.63
326.52
377.13
2.33
Net Debt
1.89
2.5
2.89
-429
BVPS
-506.5
-660.2
-
190.09

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
326.08
429.88
-24.15%
277.77
244.22
13.74%
247.06
310.18
-20.35%
203.99
215.80
-5.47%
Expenses
207.55
239.46
-13.33%
178.79
146.27
22.23%
158.57
173.50
-8.61%
142.59
134.52
6.00%
EBITDA
118.53
190.42
-37.75%
98.98
97.95
1.05%
88.49
136.68
-35.26%
61.40
81.28
-24.46%
EBIDTM
36.35%
44.30%
35.63%
40.11%
35.82%
44.06%
30.10%
37.66%
Other Income
15.35
9.38
63.65%
9.98
14.73
-32.25%
13.35
10.03
33.10%
13.68
10.31
32.69%
Interest
0.08
0.10
-20.00%
0.08
0.10
-20.00%
0.06
0.10
-40.00%
0.06
0.24
-75.00%
Depreciation
19.54
14.62
33.65%
18.75
13.26
41.40%
18.39
13.31
38.17%
17.78
13.18
34.90%
PBT
114.25
185.09
-38.27%
86.85
99.32
-12.56%
83.39
133.29
-37.44%
57.24
78.17
-26.77%
Tax
25.61
43.16
-40.66%
22.51
25.23
-10.78%
22.62
34.59
-34.61%
14.67
19.93
-26.39%
PAT
88.65
141.94
-37.54%
64.34
74.09
-13.16%
60.77
98.70
-38.43%
42.57
58.24
-26.91%
PATM
27.18%
33.02%
23.16%
30.34%
24.60%
31.82%
20.87%
26.99%
EPS
8.49
13.42
-36.74%
6.16
7.26
-15.15%
6.08
9.15
-33.55%
4.21
5.70
-26.14%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Net Sales
-
1,054.89
1,200.09
1,016.94
853.17
712.93
616.94
512.33
Net Sales Growth
-
-12.10%
18.01%
19.20%
19.67%
15.56%
20.42%
 
Cost Of Goods Sold
-
245.67
305.51
229.20
180.21
164.01
111.56
129.94
Gross Profit
-
809.22
894.57
787.74
672.96
548.92
505.38
382.39
GP Margin
-
76.71%
74.54%
77.46%
78.88%
76.99%
81.92%
74.64%
Total Expenditure
-
686.95
693.24
584.75
504.59
439.01
289.01
307.79
Power & Fuel Cost
-
116.20
112.23
104.97
97.65
71.64
39.86
37.30
% Of Sales
-
11.02%
9.35%
10.32%
11.45%
10.05%
6.46%
7.28%
Employee Cost
-
176.90
138.93
123.05
110.28
95.69
69.47
57.39
% Of Sales
-
16.77%
11.58%
12.10%
12.93%
13.42%
11.26%
11.20%
Manufacturing Exp.
-
43.94
38.74
37.39
38.44
32.48
21.97
24.21
% Of Sales
-
4.17%
3.23%
3.68%
4.51%
4.56%
3.56%
4.73%
General & Admin Exp.
-
56.34
52.19
48.57
45.72
31.09
22.52
26.19
% Of Sales
-
5.34%
4.35%
4.78%
5.36%
4.36%
3.65%
5.11%
Selling & Distn. Exp.
-
33.48
34.55
33.11
23.70
21.44
13.36
15.60
% Of Sales
-
3.17%
2.88%
3.26%
2.78%
3.01%
2.17%
3.04%
Miscellaneous Exp.
-
14.42
11.09
8.46
8.59
22.66
10.26
17.15
% Of Sales
-
1.37%
0.92%
0.83%
1.01%
3.18%
1.66%
3.35%
EBITDA
-
367.94
506.85
432.19
348.58
273.92
327.93
204.54
EBITDA Margin
-
34.88%
42.23%
42.50%
40.86%
38.42%
53.15%
39.92%
Other Income
-
52.36
44.45
33.78
35.31
23.42
13.81
31.37
Interest
-
0.82
1.04
3.18
9.80
6.13
1.05
1.17
Depreciation
-
74.46
54.37
53.59
54.03
50.05
27.52
21.25
PBT
-
345.01
495.88
409.19
320.05
241.16
313.17
213.49
Tax
-
85.42
122.91
104.46
81.93
62.59
77.83
44.53
Tax Rate
-
25.00%
24.79%
25.53%
25.60%
25.95%
24.85%
20.86%
PAT
-
260.91
371.64
308.10
240.09
174.93
234.89
168.96
PAT before Minority Interest
-
259.23
371.64
308.10
240.09
174.93
234.89
168.96
Minority Interest
-
1.68
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-
24.73%
30.97%
30.30%
28.14%
24.54%
38.07%
32.98%
PAT Growth
-
-29.79%
20.62%
28.33%
37.25%
-25.53%
39.02%
 
EPS
-
24.94
35.53
29.46
22.95
16.72
22.46
16.15

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Shareholder's Funds
2,017.06
1,812.72
1,526.65
1,290.00
1,103.22
999.37
770.23
Share Capital
10.46
10.46
10.46
10.46
9.51
9.51
9.51
Total Reserves
2,006.60
1,802.26
1,516.18
1,279.54
1,093.71
989.86
760.72
Non-Current Liabilities
47.58
37.47
31.91
32.13
54.40
77.43
55.19
Secured Loans
0.00
0.00
0.00
6.24
31.25
56.25
35.53
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
3.72
2.82
1.96
2.30
1.87
2.10
1.59
Current Liabilities
169.08
184.06
142.16
191.84
344.24
235.93
223.27
Trade Payables
101.91
113.04
94.44
93.80
83.11
46.40
71.23
Other Current Liabilities
55.92
54.97
38.32
61.57
65.98
53.58
41.79
Short Term Borrowings
0.00
0.38
0.00
0.00
4.34
5.10
0.00
Short Term Provisions
11.24
15.67
9.40
36.47
190.82
130.85
110.25
Total Liabilities
2,231.80
2,034.25
1,700.72
1,513.97
1,501.86
1,312.73
1,048.69
Net Block
788.55
794.69
575.32
592.98
572.98
546.22
239.60
Gross Block
1,162.94
1,097.16
828.31
792.80
719.95
645.33
311.19
Accumulated Depreciation
374.38
302.48
253.00
199.81
146.97
99.11
71.59
Non Current Assets
981.68
899.01
804.48
786.28
869.20
705.59
510.12
Capital Work in Progress
79.32
50.66
211.48
172.70
74.16
17.95
141.40
Non Current Investment
88.58
18.73
2.06
0.12
0.26
0.37
0.81
Long Term Loans & Adv.
17.94
12.01
12.81
11.61
220.99
140.61
127.63
Other Non Current Assets
7.28
22.93
2.81
8.87
0.82
0.45
0.67
Current Assets
1,250.11
1,135.24
896.23
727.70
632.67
607.15
538.58
Current Investments
402.06
316.54
243.70
136.93
73.47
140.99
198.11
Inventories
326.36
239.67
207.95
212.31
195.12
153.61
111.23
Sundry Debtors
460.20
521.65
349.61
273.76
232.17
177.52
183.50
Cash & Bank
13.58
1.18
47.02
43.45
88.93
60.82
2.59
Other Current Assets
47.92
28.79
26.82
45.57
42.97
74.22
43.15
Short Term Loans & Adv.
30.21
27.40
21.12
15.68
10.44
33.85
28.65
Net Current Assets
1,081.03
951.18
754.08
535.86
288.42
371.22
315.30
Total Assets
2,231.79
2,034.25
1,700.71
1,513.98
1,501.87
1,312.74
1,048.70

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Cash From Operating Activity
266.88
244.52
265.47
246.00
207.47
166.82
PBT
344.65
494.55
412.56
322.01
237.52
312.72
Adjustment
36.56
30.14
37.43
46.55
52.80
18.04
Changes in Working Capital
-13.92
-170.76
-81.18
-52.29
-22.05
-88.76
Cash after chg. in Working capital
367.29
353.94
368.82
316.28
268.26
241.99
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-100.41
-109.42
-103.35
-70.28
-60.78
-75.18
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-142.72
-159.99
-154.61
-157.95
-111.79
-195.21
Net Fixed Assets
-92.16
-108.03
-74.29
-172.49
-130.77
Net Investments
-152.50
-90.82
-106.65
-63.33
67.27
Others
101.94
38.86
26.33
77.87
-48.29
Cash from Financing Activity
-112.88
-98.77
-99.21
-85.22
-100.16
31.12
Net Cash Inflow / Outflow
11.28
-14.24
11.64
2.83
-4.48
2.74
Opening Cash & Equivalents
0.90
15.14
3.50
0.67
5.14
2.41
Closing Cash & Equivalent
12.19
0.90
15.14
3.50
0.67
5.14

Financial Ratios

Standalone /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Book Value (Rs.)
192.81
173.27
145.93
123.31
105.45
95.52
ROA
12.15%
19.90%
19.17%
15.92%
12.43%
20.89%
ROE
13.54%
22.26%
21.88%
20.06%
16.64%
26.60%
ROCE
18.04%
29.62%
29.13%
26.70%
21.66%
33.01%
Fixed Asset Turnover
0.93
1.25
1.25
1.13
1.05
1.29
Receivable days
169.86
132.49
111.87
108.22
104.87
106.80
Inventory Days
97.92
68.07
75.42
87.15
89.27
78.34
Payable days
159.68
123.94
149.88
179.16
144.10
192.42
Cash Conversion Cycle
108.11
76.63
37.41
16.22
50.04
-7.28
Total Debt/Equity
0.00
0.00
0.00
0.02
0.05
0.09
Interest Cover
419.57
475.76
130.57
33.85
39.72
300.11

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018

News Update:


  • Concord Biotech clears PPB Kenya, NDA Uganda inspection at Unit-II formulation facility
    25th Jun 2026, 12:44 PM

    The inspection took place from June 18, 2026 to June 24, 2026, and was concluded successfully

    Read More
  • Concord Biotech to acquire 27.38% stake in M/s FSGE Renewable Power
    22nd Jun 2026, 14:12 PM

    The investment is for installation of Wind Solar Hybrid Power Project in Gujarat

    Read More
  • Brazilian Health Regulatory Agency completes inspection at Concord Biotech’s API manufacturing facility in Limbasi
    12th Jun 2026, 15:30 PM

    The inspection took place from June 8, 2026 to June 12, 2026

    Read More
  • Concord Biotech gets USFDA’s nod for Tofacitinib Tablets
    10th Jun 2026, 10:40 AM

    Tofacitinib tablets are indicated for the treatment of adult patients with Moderately

    Read More
  • Concord Biotech gets USFDA nod for Mycophenolate Mofetil for Oral Suspension
    3rd Jun 2026, 10:00 AM

    The U.S. market for Mycophenolate Mofetil is around $30 million

    Read More
  • Concord Biotech - Quarterly Results
    30th May 2026, 00:00 AM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.